BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. BMC Nephrol 2018;19:361. [PMID: 30558559 DOI: 10.1186/s12882-018-1177-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Hansrivijit P, Ghahramani N. Combined rituximab and plasmapheresis or plasma exchange for focal segmental glomerulosclerosis in adult kidney transplant recipients: a meta-analysis. Int Urol Nephrol 2020;52:1377-87. [DOI: 10.1007/s11255-020-02462-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kallash M, Smoyer WE, Mahan JD. Rituximab Use in the Management of Childhood Nephrotic Syndrome. Front Pediatr 2019;7:178. [PMID: 31134169 DOI: 10.3389/fped.2019.00178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
3 Jehn U, Schütte-Nütgen K, Henke U, Pavenstädt H, Suwelack B, Reuter S. Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients. Sci Rep 2021;11:3713. [PMID: 33580120 DOI: 10.1038/s41598-021-83333-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Candelier JJ, Lorenzo HK. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res 2020;379:231-43. [PMID: 31848752 DOI: 10.1007/s00441-019-03147-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
5 Wei C, Spear R, Hahm E, Reiser J. suPAR, a Circulating Kidney Disease Factor. Front Med (Lausanne) 2021;8:745838. [PMID: 34692736 DOI: 10.3389/fmed.2021.745838] [Reference Citation Analysis]
6 Hladunewich MA, Cattran D, Sethi SM, Hayek SS, Li J, Wei C, Mullin SI, Reich HN, Reiser J, Fervenza FC. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin. Kidney Int Rep 2022;7:68-77. [PMID: 35005315 DOI: 10.1016/j.ekir.2021.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Guo Q, Yaron JR, Wallen JW 3rd, Browder KF, Boyd R, Olson TL, Burgin M, Ulrich P, Aliskevich E, Schutz LN, Fromme P, Zhang L, Lucas AR. PEGylated Serp-1 Markedly Reduces Pristane-Induced Experimental Diffuse Alveolar Hemorrhage, Altering uPAR Distribution, and Macrophage Invasion. Front Cardiovasc Med 2021;8:633212. [PMID: 33665212 DOI: 10.3389/fcvm.2021.633212] [Reference Citation Analysis]
8 Al Shamsi HR, Shaheen I, Aziz D. Management of recurrent focal segmental glomerulosclerosis (FSGS) post renal transplantation. Transplant Rev (Orlando) 2021;36:100675. [PMID: 34952298 DOI: 10.1016/j.trre.2021.100675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]